Home » Stocks » NextCure

NextCure, Inc. (NXTC)

Stock Price: $11.46 USD 0.07 (0.61%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
After-hours: $11.40 -0.06 (-0.52%) Oct 19, 7:52 PM

Stock Price Chart

Key Info

Market Cap 315.76M
Revenue (ttm) 25.97M
Net Income (ttm) -24.14M
Shares Out 27.55M
EPS (ttm) -0.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 19, 2020
Last Price $11.46
Previous Close $11.39
Change ($) 0.07
Change (%) 0.61%
Day's Open 11.51
Day's Range 11.16 - 11.60
Day's Volume 211,607
52-Week Range 7.91 - 109.00

More Stats

Market Cap 315.76M
Enterprise Value 9.02M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 27.55M
Float 16.26M
EPS (basic) -0.89
EPS (diluted) -0.94
FCF / Share -1.69
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.97M
Short Ratio 5.02
Short % of Float 12.12%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 12.16
PB Ratio 0.97
Revenue 25.97M
Operating Income -29.30M
Net Income -24.14M
Free Cash Flow -46.52M
Net Cash 306.74M
Net Cash / Share 11.13
Gross Margin -107.33%
Operating Margin -112.84%
Profit Margin -93.00%
FCF Margin -179.17%
ROA -6.70%
ROE -9.65%
ROIC -8.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 4
Overweight 0
Hold 5
Underweight 0
Sell 0

Analyst Consensus: Overweight

Price Target

(72.34% upside)
Current: $11.46
Target: 19.75
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Gross Profit6.35--
Operating Income-37.48-23.20-15.55
Net Income-33.74-22.80-15.47
Shares Outstanding15.701.371.37
Earnings Per Share-2.15-16.64-11.30
Operating Cash Flow-35.627.99-12.51
Capital Expenditures-3.37-3.06-8.65
Free Cash Flow-38.994.93-21.17
Cash & Equivalents3361369.29
Total Debt5.000.460.86
Net Cash / Debt3311358.43
Book Value321-46.94-24.41
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name NextCure, Inc.
Country United States
Employees 69
CEO Michael S. Richman

Stock Information

Ticker Symbol NXTC
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NXTC
IPO Date May 9, 2019


NextCure, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase 2 clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is headquartered in Beltsville, Maryland.